HSBC Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold

Novo Nordisk A/S (NYSE:NVO) was downgraded by research analysts at HSBC from a “buy” rating to a “hold” rating in a research report issued on Monday, Marketbeat.com reports.

NVO has been the subject of several other reports. Hsbc Global Res upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 1st. Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, August 22nd. Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating for the company. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, Barclays reaffirmed an “equal weight” rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $57.40.

Novo Nordisk A/S Stock Up 4.6%

Shares of NVO opened at $47.06 on Monday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a 50-day moving average price of $53.50 and a two-hundred day moving average price of $60.01. The stock has a market cap of $210.12 billion, a price-to-earnings ratio of 12.93, a P/E/G ratio of 2.33 and a beta of 0.65. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC raised its stake in shares of Novo Nordisk A/S by 0.3% in the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after acquiring an additional 63,341 shares during the last quarter. Capital International Investors grew its stake in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Novo Nordisk A/S by 4,190.8% in the third quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after purchasing an additional 13,658,867 shares in the last quarter. Loomis Sayles & Co. L P raised its position in Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after purchasing an additional 187,789 shares during the last quarter. Finally, Folketrygdfondet raised its position in Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after purchasing an additional 117,370 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.